Targeting Costimulatory Pathways for Tumor Immunotherapy

REFERENCES

• F. Pages, A. Berger, M. Camus, F. Sanchez-Cabo, A. Costes, R. Molidor, B. Mlecnik, A. Kirilovsky, M. Nilsson, D. Damotte, T. Meatchi, P. Bruneval, P.H. Cugnenc, Z. Trajanoski, W.H. Fridman, and J. Galon, Effector memory T-cells, early metastasis, and survival in colorectal cancer, N. Engl. J. Med., 353: 2654–2666, 2005.
   PubMed Web of Science ®Google Scholar
• S. Ostrand-Rosenberg, CD4+ T lymphocytes: A critical component of antitumor immunity, Cancer Invest., 23: 413–419, 2005.
   PubMed Web of Science ®Google Scholar
• D.M. Pardoll, Does the immune system see tumors as foreign or self? Annu. Rev. Immunol., 21: 807–839, 2003.
   PubMed Web of Science ®Google Scholar
• R.A. Morgan, M.E. Dudley, J.R. Wunderlich, , et al. Cancer regression in patients after transfer of genetically engineered lymphocytes, Science., 314: 126–129, 2006.
   PubMed Web of Science ®Google Scholar
• J.-C.D. Schwartz, X. Zhang, S.G. Nathenson, and S.C. Almo, Structural mechanisms of costimulation, Nat. Immunol., 3(5): 427–434, 2002.
   Google Scholar
• R.H. Schwartz, T cell energy, Annu. Rev. Immunol., 21: 305–334, 2003.
   PubMed Web of Science ®Google Scholar
• K.A. Frauwirth and C.B. Thompson, Activation and inhibition of lymphocytes by costimulation, J. Clin. Invest., 109(3): 295–299, 2002.
   PubMed Web of Science ®Google Scholar
• R.A. Kroczek, H.W. Mages, and A. Hutloff. Emerging paradigms of T-cell co-stimulation, Curr. Opin. Immunol., 16: 321–327, 2004.
   Google Scholar
• J.L. Riley and C.H. June, The CD28 family: A T-cell rheostat for therapeutic control of T-cell activation, Blood, 105(1): 13–21, 2005.
   Google Scholar
• D.M. Pardoll, Spinning molecular immunology into successful immunotherapy, Nat. Rev. Immunol., 2: 227–238, 2002.
   PubMed Web of Science ®Google Scholar
• S.G. Tangye, J.H. Phillips, and L.L. Lanier, The CD2-subset of the Ig superfamily of cell surface molecules: Receptor-ligand pairs expressed by NK cells and other immune cells, Semin. Immunol., 12: 149–157, 2000.
   PubMed Web of Science ®Google Scholar
• J.T. Pribila, A.C. Quale, K.L. Mueller, and Y. Shimizu, Integrins and T cell-mediated immunity, Annu. Rev. Immunol., 22: 157–180, 2004.
   PubMed Web of Science ®Google Scholar
• B. Molon, F. Gri, M. Bettella, C. Gomez-Mouton, A. Lanzavecchia, C. Martinez-A, S. Manes, and A. Viola, T cell costimulation by chemokine receptors, Nat. Immunol., 6(5): 465–471, 2005.
   Google Scholar
• R. Nurieva, S. Thomas, T. Nguyen, N. Martin-Orozco, Y. Wang, M.-K. Kaja, X.-Z. Yu, and Chen. Dong, T-cell tolerance or function is determined by combinatorial costimulatory signals, EMBO J., 25: 2623–2633, 2006.
   PubMed Web of Science ®Google Scholar
• A.V. Collins, D.W. Brodie, R.J.C. Gilbert, A. Iaboni, R. Manso-Sancho, B. Walse, D.I. Stuart, P.A. van der Merwe, and S.J. Davis, The interaction properties of costimulatory molecules revisited, Immunity, 17: 201–210, 2002.
   PubMed Web of Science ®Google Scholar
• R.J. Greenwald, G.J. Freeman, and A.H. Sharpe, The B7 family revisited, Annu. Rev. Immunol., 23: 515–548, 2005.
   PubMed Web of Science ®Google Scholar
• D.J. Lenschow, T.L. Walunas, and J.A. Bluestone, CD28/B7 system of T cell costimulation, Annu. Rev. Immunol., 14: 233–258, 1996.
   PubMed Web of Science ®Google Scholar
• C.E. Rudd and H. Schneider, Unifying concepts in CD28, ICOS and CTLA-4 coreceptor signaling, Nat. Rev. Immunol., 3: 544–556, 2003.
   PubMed Web of Science ®Google Scholar
• V.L.J. Tybulewicz, Vav-family proteins in T-cell signaling, Curr. Opin. Immunol., 17: 267–274, 2005.
   PubMed Web of Science ®Google Scholar
• W.A. Teft, M.G. Kirchhof, and J. Madrenas, A molecular perspective of CTLA-4 function, Annu. Rev. Immunol., 24, 3.1–3.33, 2005.
   Google Scholar
• A.H. Sharpe and G.J. Freeman, The B7-CD28 superfamily, Nat. Rev. Immunol., 2: 116–126, 2002.
   PubMed Web of Science ®Google Scholar
• M.L. Baroja, P.J. Darlington, B.M. Carreno, and J. Madrenas, Inhibition of T cell activation by CTLA-4: Truths and red herrings, Mod. Asp. Immunobiol., 1: 169–173, 2000.
   Google Scholar
• R.P. Sutmuller, L.M. van Duivenvoorde, A. van Elsas, T.N. Schumacher, M.E. Wildenberg, J.P. Allison, R.E. Toes, R. Offringa, and C.J. Melief, Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses, J. Exp. Med., 194(6): 823–832, 2001.
   PubMed Web of Science ®Google Scholar
• I. Tirapu, E. Huarte, C. Guiducci, A. Arina, M. Zaratiegui, O. Murillo, A. Gonzalez, C. Berasain, P. Berraondo, P. Fortes, J. Prieto, M.P. Colombo, L. Chen, and I. Melero, Low surface expression of B7-1 (CD80) is an immunoescape mechanism of colon carcinoma, Cancer Res., 66(4): 2442–2450, 2006.
   PubMed Web of Science ®Google Scholar
• A. Zippelius, P. Batard, V. Rubio-Godoy, G. Bioley, D. Lienard, F. Lejeune, D. Rimoldi, P. Guillaume, N. Meidenbauer, A. Mackensen, N. Rufer, N. Lubenow, D. Speiser, J.C. Cerottini, P. Romero, and M.J. Pittet, Effector function of human tumor-specific CD8 T cells in melanoma lesions: A state of local functional tolerance, Cancer Res., 64: 2865–2873, 2004.
   PubMed Web of Science ®Google Scholar
• J. Hodge, S. Abrams, J. Schlom, and J. Kantor, Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 costimulatory molecules, Cancer Res., 54: 5552–5555, 1994.
   PubMed Web of Science ®Google Scholar
• J. Akagi, J.W. Hodge, J.P. McLaughlin, L. Gritz, G. Mazzara, D. Kufe, J. Schlom, and J.A. Kantor, Therapeutic antitumor response after immunization with an admixture of recombinant vaccinia viruses expressing a modified, MUC1 gene and the murine T-cell costimulatory molecule B7, J. Immunother., 20(1): 38–47, 1997.
   Google Scholar
• J. Hodge, D. Grosenbach, W. Aarts, D. Poole, and J. Schlom, Vaccine therapy of established tumors in the absence of autoimmunity, Clin. Cancer Res., 9: 1837–1849, 2003.
   PubMed Web of Science ®Google Scholar
• H.L. Kaufman, G. DeRaffele, J. Mitcham, D. Moroziewicz, S.M. Cohen, K.S. Hurst-Wicker, K. Cheung, D.S. Lee, J. Divito, M. Vuolo, J. Donovan, K. Dolan, K. Manson, D. Panicali, E. Wang, H. Horig, and F.M. Marincola, Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma, J. Clin. Invest., 115: 1903–1912, 2005.
   PubMed Web of Science ®Google Scholar
• K.S. Peggs, S.A. Quezada, A.J. Korman, and J.P. Allison, Principles and use of anti-CTLA-4 antibody in human cancer immunotherapy, Curr. Opin. Immunol., 18: 206–213, 2006.
   PubMed Web of Science ®Google Scholar
• A. Korman, M. Yellin, and T. Keler, Tumor immunotherapy: Preclinical and clinical activity of anti-CTLA-4 antibodies, Curr. Opin. Invest. Drugs, 6: 582–591, 2005.
   PubMedGoogle Scholar
• A.V. Maker, G.Q. Phan, P. Attia, J.C. Yang, R.M. Sherry, S.L. Topalian, U.S. Kammula, R.E. Royal, L.R. Haworth, C. Levy, D. Kleiner, S.A. Mavroukakis, M. Yellin, and S.A. Rosenberg, Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: A Phase I/II study, Ann. Surg. Oncol., 12(12): 1005–1016, 2005.
   PubMed Web of Science ®Google Scholar
• A.V. Maker, J.C. Yang, R.M. Sherry, S.L. Topalian, U.S. Kammula, R.E. Royal, M. Hughes, M.J. Yellin, L.R. Haworth, C. Levy, T. Allen, S.A. Mavroukakis, P. Attia, and S.A. Rosenberg, Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma, J. Immunother., 29(4): 455–463, 2006.
   PubMed Web of Science ®Google Scholar
• A. Hutloff, A.M. Dittrich, K.C. Beier, B. Eljaschewitsch, R. Kraft, I. Anagnostopoulos, and R.A. Kroczek, ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28, Nature, 397, 263–266, 1999.
   PubMed Web of Science ®Google Scholar
• T. Okazaki, A. Maeda, H. Nishimura, T. Kurosaki, and T. Honjo, PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine, Proc. Natl. Acad. Sci. USA., 98: 13866–13871, 2001.
   PubMed Web of Science ®Google Scholar
• J.M. Chemnitz, R. Parry, K.E. Nichols, C.H. June, and J.L. Riley, SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation, J. Immunol., 173: 945–954, 2004.
   PubMed Web of Science ®Google Scholar
• G.L. Freeman, A.J. Long, Y. Iwai, K. Bourque, T. Chernova, H. Nishimura, L.J. Fitz, N. Malenkovich, T. Okazaki, M.C. Byrne, H.F. Horton, L. Fouser, L. Carter, V. Ling, M.R. Bowman, B.M. Carreno, M. Collins, C.R. Wood, and T. Honjo, Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation, J. Exp. Med., 192: 1027–1034, 2000.
   PubMed Web of Science ®Google Scholar
• H. Tamura, H. Dong, G. Zhu, G.L. Sica, D.B. Flies, K. Tamada, and L. Chen, B7-H1 costimulation preferentially enhances CD28-independent T-helper cell function, Blood, 97: 1809–1816, 2001.
   PubMed Web of Science ®Google Scholar
• H. Dong, S.E. Strome, D.R. Salomao, H. Tamura, F. Hirano, D.B. Flies, P.C. Roche, J. Lu, G. Zhu, K. Tamada, V.A. Lennon, E. Celis, and L. Chen, Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion, Nat. Med., 8: 793–800, 2002.
   PubMed Web of Science ®Google Scholar
• N. Watanabe, M. Gavrieli, J.R. Sedy, J.F. Yang, F. Fallarino, S.K. Loftin, M.A. Hurchla, N. Zimmerman, J. Sim, X. Zang, T.L. Murphy, J.H. Russell, J.P. Allison, and K.M. Murphy, BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1, Nat. Immunol., 4: 670–679, 2003.
   PubMed Web of Science ®Google Scholar
• A.I. Chapoval, J. Ni, J.S. Lau, R.A. Wilcox, D.B. Flies, D. Liu, H. Dong, G.L. Sica, G. Zhu, K. Tamada, and L. Chen, B7-H3: A costimulatory molecule for T-cell activation and IFN-γ production, Nat. Immunol., 2: 269–274, 2001.
   PubMed Web of Science ®Google Scholar
• W.K. Suh, B.U. Gajewska, H. Okada, M.A. Gronski, E.M. Bertram, W. Dawicki, G.S. Duncan, J. Bukczynski, S. Plyte, A. Elia, A. Wakeham, A. Itie S. Chung, J. Da Costa, S. Arya, T. Horan, P. Campbell, K. Gaida, P.S. Ohashi, T.H. Watts, S.K. Yoshinaga, M.R. Bray, M. Jordana, and T.W. Mak, The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses, Nat. Immunol., 4: 899–906, 2003.
   PubMed Web of Science ®Google Scholar
• I.H. Choi, G. Zhu, G.L. Sica, S.E. Strome, J.C. Cheville, J.S. Lau, Y. Zhu, D.B. Flies, K. Tamada, and L. Chen, Genomic organization and expression analysis of B7-H4, an immune inhibitory molecule of the B7 family, J. Immunol., 171: 4650–4654, 2003.
   PubMed Web of Science ®Google Scholar
• T.H. Watts, TNF/TNFR family members in costimulation of T cell responses, Annu. Rev. Immunol., 23: 23–68, 2005.
   PubMed Web of Science ®Google Scholar
• I.S. Grewal and R.A. Flavell, CD40 and CD154 in cell-mediated immunity, Annu. Rev. Immunol., 16: 111–135, 1998.
   PubMed Web of Science ®Google Scholar
• T. Geldart and T. Illidge, Anti-CD40 monoclonal antibody, Leuk. Lymphoma., 46(8): 1105–1113, 2005.
   PubMed Web of Science ®Google Scholar
• A.G. Eliopoulos, C. Davies, P.G. Knox, N.J. Gallagher, S.C. Afford, D.H. Adams, and L.S. Young, CD40 induces apoptosis in carcinoma cells through activation of cytotoxic ligands of the tumor necrosis factor superfamily, Mol. Cell. Biol., 20(15): 5503–5515, 2000.
   PubMed Web of Science ®Google Scholar
• Y. Xu and G. Song, The role of CD40-CD154 interaction in cell immunoregulation, J. Biomed. Sci., 11: 426–438, 2004.
   Google Scholar
• Y. Morel, A. Truneh, R.W. Sweet, D. Olive, and R.T. Costello, The TNF superfamily members LIGHT and CD154 (CD40 ligand) costimulate induction of dendritic cell maturation and elicit specific CTL activity, J. Immunol., 167: 2479–2486, 2001.
   PubMed Web of Science ®Google Scholar
• M. Bereta, J. Bereta, J. Park, F. Medina, H. Kwak, and H.L. Kaufman, Immune properties of recombinant vaccinia virus encoding CD154 (CD40L) are determined by expression of virally encoded CD40L and the presence of CD40L protein in viral particles, Cancer Gene. Ther., 11: 808–818, 2004.
   PubMedGoogle Scholar
• R.H. Vonderheide, J.P. Dutcher, J.E. Anderson, S.G. Eckhardt, K.F. Stephans, B. Razvillas, S. Garl, M.D. Butine, V.P. Perry, R.J. Armitage, R. Ghalie, D.A. Caron, and J.G. Gribben, Phase I study of recombinant human CD40 ligand in cancer patients, J. Clin. Oncol., 19(13): 3280–3287, 2001.
   PubMed Web of Science ®Google Scholar
• S. Takahashi, P. Yotnda, R.F. Rousseau, Z. Mei, S. Smith, D. Rill, A. Younes, and M.K. Brenner, Transgenic expression of CD40L and interleukin-2 induces an autologous antitumor immune response in patients with non-Hodgkin's lymphoma, Cancer Gene. Ther., 8(5): 378–387, 2001.
   Google Scholar
• K. Tamada, K. Shimozaki, A.I. Chapoval, G. Zhu, G. Sica, D. Flies, T. Boone, H. Hsu, Y.X. Fu, S. Nagata, J. Ni, and L. Chen, Modulation of T-cell-mediated immunity in tumor and graft-versus-host disease models through the LIGHT co-stimulatory pathway, Nat. Med., 6: 283–289, 2000.
   PubMedGoogle Scholar
• P. Yu, Y. Lee, W. Liu, R.K. Chin, J. Wang, A. Schietinger, M. Philip, H. Schreiber, and Y.X. Fu, Priming of naïve T cells inside tumors leads to eradication of established tumors, Nat. Immunol., 5: 141–149, 2004.
   PubMed Web of Science ®Google Scholar
• M. Croft, Co-stimulatory members of the TNFR family: Keys to effective T-cell immunity? Nat. Rev. Immunol., 3: 609–620, 2003.
   PubMed Web of Science ®Google Scholar
• J. Hendriks, L.A. Gravestein, K. Tesselaar, R.A. van Lier, T.N. Schumacher, and J. Borst, CD27 is required for generation and long-term maintenance of T cell immunity, Nat. Immunol., 1: 433–440, 2000.
   PubMed Web of Science ®Google Scholar
• P.R. Rogers, J. Song, I. Gramaglia, N. Kileen, and M. Croft, OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells, Immunity, 15: 445–455, 2001.
   PubMed Web of Science ®Google Scholar
• G. Gri, E. Gallo, E. Di Carlo, P. Musiani, and M.P. Colombo, OX40 ligand-transduced tumor cell vaccines synergizes with GM-CSF and requires CD40-APC signaling to boost the host T cell antitumor response, J. Immunol., 170: 99–106, 2003.
   PubMed Web of Science ®Google Scholar
• A.D. Weinberg, M.M. Rivera, R. Prell, A. Morris, T. Ramstad, J.T. Vetto, W.J. Urba, G. Alvord, C. Bunce, and J. Shields, Engagement of the OX-40 receptor in vivo enhances antitumor immunity, J. Immunol., 164: 2160–2169, 2000.
   PubMed Web of Science ®Google Scholar
• I. Metero, S. Hervas-Stubbs, M. Glennie, D.M. Pardoll, and L. Chen, Immunostimulatory monoclonal antibodies for cancer therapy, Nat. Rev. Cancer, 7: 95–106, 2007.
   Google Scholar
• T. Wen, J. Bukczynksi, and T.H. Watts, 4-1BB ligand-mediated costimulation of human T-cells induces CD4 and CD8 T cell expansion, cytokine production and the development of cytolytic effector function, J. Immunol., 168: 4897–4906, 2002.
   PubMed Web of Science ®Google Scholar
• H.W. Lee, S.J. Park, B.K. Choi, H.H. Kim, K.O. Nam, and B.S. Kwon, 4-1BB promotes the survival of CD8+ T lymphocytes by increasing expressing of Bcl-xL and Bfl-1, J. Immunol., 169: 4882–4888, 2002.
   PubMed Web of Science ®Google Scholar
• B.K. Choi, J.S. Bae, E.M. Choi, W.J. Kang, S. Sakaguchi, D.S. Vinay, and B.S. Kwon, 4-1BB-dependent inhibition of immunosuppression by activated CD4+ CD25+ T cells, J. Leukoc. Biol., 75: 785–791, 2004.
   PubMedGoogle Scholar
• C. Kudo-Saito, J.W. Hodge, H. Kwak, S. Kim-Schulze, J. Schlom, and H.L. Kaufman, 4-1BB ligand enhances tumor-specific immunity of poxvirus vaccines, Vaccine. 24(23): 4975–4986, 2006.
   Google Scholar
• H.M. Toennies, J.M. Green, and R.H. Arch, Expression of CD30 and OX40 on T lymphocyte subsets is controlled by distinct regulatory mechanisms, J. Leukoc. Biol., 75: 350–357, 2004.
   Google Scholar
• E.R. Podack, N. Strbo, V. Sotosec, and H. Muta, CD30-governor of memory T cells? Ann. NY. Acad. Sci., 975: 101–113, 2002.
   PubMed Web of Science ®Google Scholar
• F. Kanamaru, P. Youngnak, M. Hashiguchi, T. Nishioka, T. Takahashi, S. Sakaguchi, I. Ishikawa, and M. Azuma, Costimulation via glucocorticoid-induced TNF receptor in both conventional and CD25+ regulatory CD4+ T cells, J. Immunol., 172: 7306–7314, 2004.
   PubMed Web of Science ®Google Scholar
• A.D. Cohen, A. Diab, M.A. Perales, , et al., Agonistic anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity, Cancer Res., 66: 4904–4912, 2006.
   PubMed Web of Science ®Google Scholar
• P.A. Van der Merwe and S.J. Davis, Molecular interactions mediating T cell antigen recognition, Annu. Rev. Immunol., 21: 659–684, 2003.
   PubMed Web of Science ®Google Scholar
• T.N. Sims and M.L. Dustin, The immunological synapse: Integrins take the stage, Immunol. Rev., 186: 100–117, 2002.
   PubMed Web of Science ®Google Scholar
• Y. Samstag and G. Nebl, Ras initiates phosphatidyl-inositol-3-kinase (PI3K)/PKB mediated signaling pathways in untransformed human peripheral blood T lymphocytes, Adv. Enzyme. Regul., 45: 52–62, 2005.
   PubMedGoogle Scholar
• P. Eissman, L. Beauchamp, J. Wooters, J.C. Tilton, E.O. Long, and C. Watzl, Molecular basis for positive and negative signaling by the natural killer cell receptor 2B4 (CD244) Blood., 105(12): 4722–4729, 2005.
   Google Scholar
• D. Howie, S. Okamoto, S. Rietdijk, K. Clarke, N. Wang, C. Gullo, J.P. Bruggeman, S. Manning, A.J. Coyle, E. Greenfield, V. Kuchroo, and C. Terhorst, The role of SAP in murine CD150 (SLAM)-mediated T-cell proliferation and interferon γ production, Blood., 100(8): 2899–2906, 2002.
   Google Scholar
• R. Roncagalli, J.E. Taylor, S. Zhang, X. Shi, R. Chen, M.E. Cruz-Munoz, L. Yin, S. Latour, and A. Veillette, Negative regulation of natural killer cell function by EAT-2, a SAP-related adaptor, Nat. Immunol., 6(10): 1002–1010, 2005.
   PubMed Web of Science ®Google Scholar
• E. Assarsson, T. Kambayashi, C.M. Persson, B.J. Chambers, and H.G. Ljunggren, 2B4/CD48-mediated regulation of lymphocyte activation and function, J. Immunol., 175: 2045–2049, 2005.
   Google Scholar
• T. Lebedeva, M.L. Dustin, and Y. Sykulev, ICAM-1 co-stimulates target cells to facilitate antigen presentation, Curr. Opin. Immunol., 17: 251–258, 2005.
   PubMed Web of Science ®Google Scholar
• R. Alon and S. Feigelson, From rolling to arrest on blood vessels: Leukocyte tap dancing on endothelial integrin ligands and chemokines at sub-second contacts, Semin. Immunol., 14(2): 93–104, 2002.
   Google Scholar
• D.F. Kucik, Rearrangement of integrins in avidity regulation by leukocytes, Immunol. Res., 26(1–3): 199–206, 2002.
   Google Scholar
• H.T. Ni, M.J. Deeths, W. Li, D.L. Meuller, and M.F. Mescher, Signaling pathways activated by leukocyte function-associated Ag-1-dependent costimulation, J. Immunol., 162: 5183–5189, 1999.
   PubMedGoogle Scholar
• J.L. Gaglia, E.A. Greenfield, A. Matoo, A.H. Sharpe, G.J. Freeman, and V.K. Kuchroo, Intercellular adhesion molecule 1 is critical for activation of CD28-deficient T-cells, J. Immunol., 165: 6091–6098, 2000.
   Google Scholar
• B. Sherry and A. Cerami, Small cytokine superfamily, Curr. Opin. Immunol., 3(1): 56–60, 1991.
   Google Scholar
• D. Rossi and A. Zlotnik, The biology of chemokines and their receptors, Annu. Rev. Immunol., 18: 217–242, 2000.
   PubMed Web of Science ®Google Scholar
• S.G. Ward, K. Bacon, and J. Westwick, Chemokines and T lymphocytes: More than an attraction, Immunity, 9: 1–11, 1998.
   PubMed Web of Science ®Google Scholar
• S.A. Luther and J.G. Cyster, Chemokines as regulators of T cell differentiation, Nat. Immunol., 2(2): 102–107, 2001.
   PubMed Web of Science ®Google Scholar
• S.S. Karnik, C. Gogonea, S. Patil, Y. Saad, and T. Takezako, Activation of G-protein-coupled receptors: A common molecular mechanism, Trends Endocrinol. Metab., 14(9): 431–471, 2003.
   PubMedGoogle Scholar
• F. Sallusto, C.R. Mackay, and A. Lanzavecchia, The role of chemokine receptors in primary, effector, and memory immune responses, Annu. Rev. Immunol., 18: 593–620, 2000.
   PubMed Web of Science ®Google Scholar
• B. Moser, M. Wolf, A. Walz, and P. Loetscher, Chemokines: Multiple levels of leukocyte migration control, Trends Immunol., 25(2): 76–84, 2004.
   Google Scholar
• D.D. Taub, S.M. Turcovski-Corrales, M.L. Key, D.L. Longo, and W.J. Murphy, Chemokines and T lymphocyte activation: I. β chemokines costimulate human T lymphocyte activation in vitro, J. Immunol., 156: 2095–2103, 1996.
   PubMed Web of Science ®Google Scholar
• B.J. Marsland, P. Battig, M. Bauer, C. Ruedl, U. Lassing, R.R. Beerli, K. Dietmeier, L. Ivanova, T. Pfister, L. Vogt, H. Nakano, C. Nembrini, P. Saudan, M. Kopf, and M.F. Bachmann, CCL19 and CCL21 induce a potent proinflammatory differentiation program in licensed dendritic cells, Immunity, 22: 493–505, 2005.
   PubMed Web of Science ®Google Scholar
• K. Flanagan, D. Moroziewicz, H. Kwak, H. Horig, and H.L. Kaufman, The lymphoid chemokine CCL21 costimulates naïve T cell expansion and Th1 polarization of non-regulatory CD4+ T cells, Cell. Immunol., 231: 75–84, 2004.
   PubMed Web of Science ®Google Scholar
• K. Flanagan and H.L. Kaufman, Chemokines in tumor immunotherapy, Front. Biosci., 11: 1024–1030, 2006.
   Google Scholar
• J.J. Mule, M. Custer, J.C. Averbook, J. Yang, J.S. Weber, D.V. Goeddel, S.A. Rosenberg, and T.J. Schall, RANTES secretion by gene-modified tumor cells results in loss of tumorigenicity in vivo: Role of immune cell subpopulations, Hum. Gene. Ther., 7(13): 1545–1553, 1996.
   PubMed Web of Science ®Google Scholar
• E. Azenshtein, G. Luboshits, S. Shina, E. Neumark, D. Shabazian, M. Weil, N. Wigler, I. Keydar, and A. Ben-Baruch, The CC chemokine RANTES in breast carcinoma progression: Regulation of expression and potential mechanisms of promalignant activity, Cancer Res., 62: 1093–1102, 2002.
   PubMed Web of Science ®Google Scholar
• K. Flanagan, R.T. Glover, H. Horig, W. Yang, and H.L. Kaufman, Local delivery of recombinant vaccinia virus expressing secondary lymphoid chemokine (SLC) results in a CD4 T-cell dependent antitumor response, Vaccine, 22(21–22): 2894–2903, 2004.
   Google Scholar
• C.J. Kirk, D. Hartigan-O'Connor, B.J. Nickoloff, J.S. Chamberlain, M. Giedlin, L. Aukerman, and J.J. Mule, T cell-dependent antitumor immunity mediated by secondary lymphoid tissue chemokine: Augmentation of dendritic cell-based immunotherapy, Cancer Res., 61(5): 2062–2070, 2001.
   Google Scholar
• S.C. Yang, R.K. Batra, S. Hillinger, K.L. Reckamp, R.M. Strieter, S.M. Dubinett, and S. Sharma, Intrapulmonary administration of CCL21 gene-modified dendritic cells reduces tumor burden in spontaneous murine bronchoalveolar cell carcinoma, Cancer Res., 66(6): 3205–3213, 2006.
   PubMed Web of Science ®Google Scholar
• C.J. Kirk, D. Harigan-O'Connor, and J.J. Mule, The dynamics of the T-cell antitumor response: Chemokine-secreting dendritic cells can prime tumor-reactive T cells extranodally, Cancer Res., 61: 8794–8802, 2001.
   PubMed Web of Science ®Google Scholar
• J.W. Hodge, J.W. Greiner, K-Y. Tsang, H. Sabzevari, C. Kudo-Saito, D.W. Grosenbach, J.L. Gulley, P.M. Arlen, J.L. Marshall, D. Panicalli, and J. Schlom, Costimulatory molecules as adjuvants for immunotherapy, Front. Biosci., 11: 788–803, 2006.
   PubMed Web of Science ®Google Scholar
• A.G. Wingren, E. Parra, M. Varga, T. Kalland, H.O. Sjorgren, G. Hedlund, and M. Dohlsten, T cell activation pathways: B7, LFA-3, and ICAM-1 shape unique T cell profiles, Crit. Rev. Immunol., 15: 235–253, 1995.
   PubMed Web of Science ®Google Scholar
• J.W. Hodge, H. Sabzevari, A.G. Yafal, L. Gritz, M.G. Lorenz, and J. Schlom, A triad of costimulatory molecules synergize to amplify T-cell activation, Cancer Res., 59: 5800–5807, 1999.
   PubMed Web of Science ®Google Scholar
• J.W. Hodge, D.W. Grosenbach, W.M. Aarts, D.J. Poole, and J. Schlom, Vaccine therapy of established tumors in the absence of autoimmunity, Clin. Cancer Res., 9: 1837–1849, 2003.
   PubMed Web of Science ®Google Scholar
• D.W. Grosenbach, J.C. Barrientos, J. Schlom, and J.W. Hodge, Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects, Cancer Res., 61: 4497–4505, 2001.
   PubMed Web of Science ®Google Scholar
• M.A. Alexander-Miller, G.R. Leggatt, and J.A. Berzofsky, Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy, Proc. Natl. Acad. Sci. U.S.A., 93: 4102–4107, 1996.
   PubMed Web of Science ®Google Scholar
• H.L. Kaufman, Manipulating the local tumor microenvironment with poxviruses expressing costimulatory molecules, Ann. N.Y. Acad. Sci., 1062: 41–50, 2005.
   PubMed Web of Science ®Google Scholar
• B. Levy, D. Panicalli, and J. Marshall, TRICOM: Enhanced vaccines as anticancer therapy, Expert Rev. Vaccines, 3: 397–402, 2004.
   PubMedGoogle Scholar
• D.W. Grosenbach, J. Schlom, L. Gritz, A. Gomez, Yafal, and J.W. Hodge, A recombinant vector expressing transgenes for four T-cell costimulatory molecules (OX40L, B7-1, ICAM-1, LFA-3) induces sustained CD4+ and CD8+ T-cell activation, protection from apoptosis, and enhanced cytokine production, Cell. Imunol., 222: 45–57, 2003.
   PubMedGoogle Scholar
• M.G. Lorenz, J.A. Kantor, J. Schlom, and J.W. Hodge, Anti-tumor immunity elicited by a recombinant vaccinia virus expressing CD70 (CD27L) Hum. Gene. Ther., 10: 1095–1103, 1999.
   PubMed Web of Science ®Google Scholar
• H. Abken, A. Hombach, C. Heuser, K. Kronfeld, and B. Seliger, Tuning tumor-specific T-cell activation: A matter of costimulation? Trends Immunol., 23(5): 240–245, 2002.
   PubMedGoogle Scholar